Get the Stockscreener App
14.93
6.72%
0.94
After Hours:
14.70
-0.23
-1.54%
Xencor Inc stock is traded at $14.93, with a volume of 788.32K.
It is up +6.72% in the last 24 hours and up +20.11% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$13.99
Open:
$13.83
24h Volume:
788.32K
Relative Volume:
0.70
Market Cap:
$1.06B
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-5.1661
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+7.41%
1M Performance:
+20.11%
6M Performance:
+83.42%
1Y Performance:
-36.47%
1-Day Range:
$13.73
$15.09
1-Week Range:
$13.57
$15.29
52-Week Range:
$6.92
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
14.93 | 999.03M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Is Xencor Inc. (XE9) stock undervalued historicallyJuly 2025 Levels & Real-Time Buy Signal Alerts - newser.com
Why Xencor Inc. stock remains on buy listsDip Buying & Fast Momentum Stock Entry Tips - newser.com
Should you hold or exit Xencor Inc. nowWeekly Trade Report & Weekly Breakout Watchlists - newser.com
What candlestick patterns are forming on Xencor Inc.Market Rally & Verified Momentum Stock Watchlist - newser.com
What to expect from Xencor Inc. in the next 30 days2025 Investor Takeaways & Target Return Focused Picks - newser.com
Los Angeles Capital Management LLC Purchases 83,143 Shares of Xencor, Inc. $XNCR - MarketBeat
Tick level data insight on Xencor Inc. volatilityQuarterly Trade Report & Expert Verified Stock Movement Alerts - newser.com
Can Xencor Inc. stock continue upward trendMarket Activity Report & Safe Investment Capital Preservation Plans - newser.com
Is Xencor Inc. (XE9) stock nearing a technical breakoutJuly 2025 Opening Moves & Technical Pattern Alert System - newser.com
Why analysts remain bullish on Xencor Inc. stock2025 AllTime Highs & Verified Momentum Stock Alerts - newser.com
How Xencor Inc. stock compares to growth peersGold Moves & High Accuracy Investment Signals - newser.com
Does Xencor’s Sharply Reduced Loss in Q3 2025 Signal a Turnaround for XNCR? - simplywall.st
How Xencor Inc. (XE9) stock benefits from digital adoptionQuarterly Trade Review & Accurate Technical Buy Alerts - newser.com
Xencor (XNCR): Assessing Valuation After Net Losses Narrow Sharply in Latest Earnings - Yahoo Finance
Will Sharply Reduced Net Losses Signal a Turning Point for Xencor's (XNCR) Path to Profitability? - Yahoo Finance
Can a trend reversal in Xencor Inc. lead to recoveryTrade Volume Summary & Verified Technical Trade Signals - newser.com
Xencor (NASDAQ:XNCR) Shares Up 8.7%What's Next? - MarketBeat
Xencor at TD Cowen Summit: Strategic Focus on Oncology and Autoimmune - Investing.com Nigeria
Xencor Inc. stock trend forecastWeekly Trend Recap & Capital Efficient Trade Techniques - newser.com
Will Xencor Inc. (XE9) stock return to pre crash levelsJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
Positive readouts validate pipelines, fuel drug developer rally - BioWorld MedTech
Why institutional investors increase stakes in Xencor Inc. (XE9) stockJuly 2025 Big Picture & Low Drawdown Trading Techniques - newser.com
Xencor to Participate at Upcoming Investor Conferences - Business Wire
Is Xencor Inc. stock gaining market shareRate Cut & Free Weekly Watchlist of Top Performers - newser.com
Cantor Fitzgerald Predicts Increased Earnings for Xencor - MarketBeat
Wedbush Estimates Xencor's FY2025 Earnings (NASDAQ:XNCR) - MarketBeat
FY2025 Earnings Estimate for Xencor Issued By William Blair - MarketBeat
Leerink Partnrs Increases Earnings Estimates for Xencor - MarketBeat
Published on: 2025-11-09 23:13:10 - newser.com
Can volume confirm reversal in Xencor Inc.2025 Momentum Check & Daily Stock Momentum Reports - newser.com
Xencor (NASDAQ:XNCR) Price Target Cut to $18.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Wedbush Reaffirms "Outperform" Rating for Xencor (NASDAQ:XNCR) - MarketBeat
Xencor (NASDAQ:XNCR) Given New $19.00 Price Target at Royal Bank Of Canada - MarketBeat
Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
Tools to assess Xencor Inc.’s risk profileWeekly Market Summary & Target Return Focused Stock Picks - newser.com
Xencor (XNCR) Gets a Hold from Bank of America Securities - The Globe and Mail
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):